RECRUITING

Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)

Description

The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of lipid accumulation.

Conditions

Idiopathic Pulmonary Arterial HypertensionHeritable Pulmonary Arterial HypertensionPulmonary Arterial Hypertension Associated With Connective Tissue Disease
Talk to us

Related Conditions:

Idiopathic Pulmonary Arterial HypertensionHeritable Pulmonary Arterial HypertensionPulmonary Arterial Hypertension Associated With Connective Tissue Disease

Study Overview

On this page

Study Details

Study overview

The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of lipid accumulation.

Clinical and Mechanistic Understanding of Right Ventricular Steatosis in Pulmonary Arterial Hypertension (PAH)

Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)

Condition
Idiopathic Pulmonary Arterial Hypertension
Intervention / Treatment

-

Contacts and Locations

Nashville

Vanderbilt University Medical Center, Nashville, Tennessee, United States, 37232

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * ≥ 18 years old
  • * Diagnosed with idiopathic, heritable, connective tissue disease-associated PAH, associated pulmonary arterial hypertension (PAH), or drug-or toxin-associated PAH according to World Health Organization (WHO) consensus recommendations.
  • * Stable PAH-specific medication regimen for three months prior to enrollment. Adjustments in IV prostacyclin for side effect management are allowed. Diuretic adjustments are permitted.
  • * WHO Functional Class I-III
  • * Ambulatory
  • * Able to have an MRI/MRS, perform a 6MWD test, and cardiopulmonary exercise test
  • * Pregnancy
  • * Diagnosis of PAH etiology other than idiopathic, heritable, connective tissue disease - associated PAH or associated with drugs and toxins
  • * WHO Functional class IV heart failure
  • * Requirement for continuous oxygen
  • * Unable to have an MRI/MRS, perform a 6MWD test, or cardiopulmonary exercise test.
  • * Patients with implanted/embedded ferromagnetic material that would preclude cardiac MRI

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Vanderbilt University Medical Center,

Evan Brittain, MD, MSCI, PRINCIPAL_INVESTIGATOR, Vanderbilt University Medical Center

Study Record Dates

2027-09-30